Two leading drug makers are seeking to enter a lawsuit aimed at stopping their efforts to restrict 340B discounts on drugs offered via contract pharmacies, coming as clinics that filed the suit ask a federal court to demand HHS take immediate steps to restore the discounts.

A new Commonwealth Fund report finds the share of income that middle-income families spend on employer-sponsored insurance (ESI) continues to rise, with premiums and deductibles accounting for about 11.5% of median household income in 2019, up from 9.1% of income a decade earlier.

States and local governments hope to establish a stronger partnership with federal regulators, through more meetings and a robust White House Office of Intergovernmental Affairs under the incoming Biden administration, to help them respond to the pandemic and turn around the economy.

Dozens of groups that represent employers and benefit advisors tell lawmakers that even if they’re unable to reach an agreement to address surprise billing, they should still pass a suite of less-controversial provisions on transparency, drug pricing and other reforms included in the Senate health committee's bipartisan Lower Health Care Costs Act (S. 1985).

Public health experts and drug makers say the Trump administration should be doing more to increase the public’s trust in upcoming COVID-19 vaccines and are awaiting a plan from the incoming Biden administration detailing how it will encourage people to be vaccinated.

The White House Office of Budget and Management is reviewing a final FDA guidance that aims to assist manufacturers with developing proprietary names for drugs and biologics that could help prevent medication errors.

HHS’ plan to end FDA’s Unapproved Drugs Initiative could save the U.S. healthcare system between $7.5 billion and $26.6 billion over five years, according to health care consultant firm Vizient.

President-elect Joe Biden’s pledge that his administration will only contract with companies that make products domestically ​could negatively impact generic drug makers, but the incoming Biden administration's policy generally is not expected to affect coronavirus drugs and vaccines because nearly all of the contracts signed by the Trump administration are for products that already are made in the United States.